Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27716154 | 0.89 | SLC5A2 (0.34) | SLC5A2 | |
| SCHEMBL4622856 | 0.86 | SLC5A2 (0.40) | SLC5A2SLC6A2SLC6A4SLC6A3LOXL2 | |
| SCHEMBL4622359 | 0.86 | LOXL2 (0.46) | SLC5A2HTR2CHTR2AHTR2BSLC6A2 | |
| SCHEMBL13970077 | 0.83 | SLC5A2 (0.38) | SLC5A2HTR2CHTR2ASLC6A2SLC6A4 | |
| SCHEMBL1777 | 0.81 | KDM1A (0.35) | SLC6A4 | |
| SCHEMBL27508666 | 0.78 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL27840083 | 0.78 | FADS1 (0.37) | HTR2CHTR2AHTR2B | |
| SCHEMBL6096441 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7163573 | 0.75 | SLC5A2 (0.39) | SLC5A2HTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL5936386 | 0.74 | MEN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296970-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2008-03-19 | — | — | EP | disclosed |
| US-6660873-B2 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2003-12-09 | — | — | US | disclosed |
| US-20030134895-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2003-07-17 | — | — | US | disclosed |
| EP-1296970-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001085712-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134895-A1 | Method for the preparation of citalopram | MAOB, MAOA, TPH1 | SLC5A2 1388/4885HTR2C 147/4885HTR2A 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.